Iovance (IOVA)
Biotech
Close on Nov 12, 2026 (from our latest Long View update): $7.63
- Market value
- $3.5Bat the Nov 12 close
- Revenue growth
- +51%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- −57%12 months to Sep 30, 2026 (10-Q)
- Net cash
- $376Mat Sep 30, 2026
- Worst fall since listing
- −99.4%Jun 7, 2011 to Apr 12, 2013; not back to that high (−95.4% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
The Long View
Iovance bought Proleukin in 2023 and won US approval for Amtagvi in 2024, funded largely by selling new shares.
▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash
Updated Nov 12, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for Iovance, FY2009–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $1M in FY2023 to $264M in FY2025.
Free cash flow was positive in 1 of the 17 years shown; FY2025: −$336M.
Margins
Margins are not charted: in FY2025 the operating loss (−$403M) was larger than revenue ($264M). The table has each year's figures.
Diluted share count
The diluted share count rose 158% from FY2020 to FY2025, to 357M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $264M | 34% | −153% | −$391M | −$302M | $34M | −$336M |
| FY2024 | $164M | 43% | −241% | −$372M | −$353M | $11M | −$364M |
| FY2023 | $1M | 13% | −38735% | −$444M | −$362M | $22M | −$384M |
| FY2022 | — | — | — | −$396M | −$293M | $20M | −$313M |
| FY2021 | — | — | — | −$342M | −$228M | $38M | −$266M |
| FY2020 | — | — | — | −$260M | −$205M | $47M | −$252M |
| FY2019 | — | — | — | −$198M | −$159M | $7M | −$166M |
| FY2018 | $0 | — | — | −$124M | −$101M | $1M | −$102M |
| FY2017 | $0 | — | — | −$92M | −$79M | $1M | −$80M |
| FY2016 | $0 | — | — | −$53M | −$33M | $2M | −$34M |
| FY2015 | $0 | — | — | −$28M | −$18M | $1M | −$20M |
| FY2014 | $0 | — | — | −$12M | $9M | $2M | $7M |
| FY2013 | $0 | — | — | −$25M | −$4M | $0.0M | −$4M |
| FY2012 | $0 | — | — | −$3M | −$2M | $0 | −$2M |
| FY2011 | $0 | — | — | −$26M | −$6M | $0.0M | −$6M |
| FY2010 | $0 | — | — | −$2M | −$0.6M | $0 | −$0.6M |
| FY2009 | $0 | — | — | −$0.0M | −$0.0M | $0 | −$0.0M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 357M | $297M | $1M | $62M | — | — |
| FY2024 | 290M | $324M | $1M | $110M | — | — |
| FY2023 | 235M | $280M | $1M | $63M | — | — |
| FY2022 | 159M | $472M | $1M | $84M | — | — |
| FY2021 | 153M | $596M | $1M | $70M | — | — |
| FY2020 | 138M | $629M | — | $41M | — | — |
| FY2019 | 124M | $307M | — | $24M | — | — |
| FY2018 | — | $469M | — | $20M | — | — |
| FY2017 | — | $145M | — | $12M | — | — |
| FY2016 | — | $107M | — | $19M | — | — |
| FY2015 | — | $34M | — | $9M | — | — |
| FY2014 | — | $45M | — | $4M | — | — |
| FY2013 | — | $20M | — | $3M | — | — |
| FY2012 | — | $0 | — | $3M | — | — |
| FY2011 | — | $0.5M | — | $15M | — | — |
| FY2010 | — | $1M | — | $0.1M | — | — |
| FY2009 | — | $0.0M | — | $0 | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 12, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
- Gross profit is revenue minus cost of revenue (the 10-K does not report a gross profit line).
- Diluted shares for FY2019-2025 are tagged in thousands in the 10-K; shown in shares (×1,000).
Returns by year
| Year | IOVA | S&P 500 |
|---|---|---|
| 2019 | +212.8% | +31.5% |
| 2020 | +67.6% | +18.4% |
| 2021 | −58.9% | +28.7% |
| 2022 | −66.5% | −18.1% |
| 2023 | +27.2% | +26.3% |
| 2024 | −9.0% | +25.0% |
| 2025 | −63.1% | +17.9% |
| 2026 to date | +167.8% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- SLS SELLAS Up 156.4%
- TNGX Tango Therapeutics Down 16.4%
- VKTX Viking Therapeutics
- XNCR Xencor Up 15.9%
- VERA Vera Down 1.2%
- ARWR Arrowhead Down 15.3%
Show all 17
- NRIX Nurix Therapeutics Down 38.2%
- AGIO Agios Down 9.9%
- IMCR Immunocore Up 9.1%
- KRYS Krystal Down 11%
- CORT Corcept Therapeutics Down 20.1%
- TGTX TG Therapeutics Up 5.9%
- MDGL Madrigal Down 8.1%
- ORIC ORIC Pharmaceuticals Down 32%
- ALNY Alnylam
- GMAB Genmab Up 28.3%
- MRNA Moderna Down 17.6%
Questions about Iovance
- Why did Iovance stock fall on Oct 29, 2026?
- Iovance called the results of its trial in previously treated non-squamous non-small-cell lung cancer, a major category of lung cancer, positive on Wednesday evening, without numbers, and the stock rose about 12% after hours; on Thursday it fell 35% once the data were out. Tumors shrank in about 1 in 4 patients, close to an earlier update, with most responses in a small subgroup identified after the fact. Iovance will test that subgroup in a new group of patients within the same trial, while keeping its broader 2027 filing plan. Read the article →
- Does Iovance need to raise money?
- At its past rate of cash use, its cash would run below zero around Q2 2028; the company says: into 2029. Companies usually raise money well before that. Read the Long View →
- How fast is Iovance's share count growing?
- Shares outstanding (common plus convertible preferred, as converted) rose 190% from Dec 31, 2021 to Sep 30, 2026, about 25.2% a year compounded. Read the Long View →